Innovent Bio and Lilly Announce Third China Approval for PD-1

Suzhou Innovent Biologics and its partner, Eli Lilly, announced their jointly developed anti-PD-1 was approved in China as a first-line therapy for NSCLC. China approved Tyvyt® (sintilimab injection) in combination with gemcitabine and platinum chemotherapy as a first-line therapy for unresectable locally advanced or metastatic squamous non-small cell lung cancer. It is the third China approval for Tyvyt. Previously, Tyvyt was approved for classical Hodgkin's lymphoma and nonsquamous non-small cell lung cancer. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //